BG-12 In MS, Two Long-Acting Hemophilia Drugs Key To Scangos’ Revitalized Biogen Idec
This article was originally published in The Pink Sheet Daily
An R&D overhaul trimmed 17 candidates from pipeline, but as several late-stage programs near potential approval, the biotech says it will resume focus on discovery and validation of new targets.
You may also be interested in...
Biogen hopes to submit marketing applications in the U.S. and Europe for both MS therapy BG-12 and its therapies for hemophilia A and B in 2012, with launches possible in early and mid-2013.
India’s Cadila Healthcare, which has been suffering on the earnings front, is amalgamating four subsidiaries under its roof to reduce overheads from managing separate entities and avoid duplication of efforts after posting weak second-quarter earnings.